Japan's Nikkei notches a new record after the country's Prime Minister secures a powerful mandate in snap elections.
Plus, Epstein files revelations bring down the top aid to Britain's Prime Minister.
What we're seeing in the UK, which is different to the US,
is a very real fallout at the Epstein Piles in terms of people having their professional careers curtailed.
And SpaceX puts the Red Planet on hold, setting its sights on the moon.
It's Monday, February 9th.
I'm Luke Vargas for The Wall Street Journal, and here is the AM edition of What's News,
the top headlines and business stories moving your world today.
Japan's benchmark Nikkei Stock Index has surged to a record high after Prime Minister Sanae Takeichi won a powerful mandate to deepen ties with the U.S.
and rev up Japan's economy.
The landslide victory in yesterday's elections gives Takeichi's government a more than two-thirds majority in Japan's lower house and the ability to overrule the smaller upper house to push through its agenda.
Shares in weight loss drug maker Novo Nordisk are rallying today after American telehealth company Hymns and Hers dropped its plan to offer a knockoff version of We Govee over the weekend.
The move came after the Food and Drug Administration threatened to restrict access to the ingredients that compounding pharmacies need to copy popular GLP-1 medicines.
In response, Hims & Hers said it's always operated in compliance with the law,
while investors sent its shares down more than 15% in off-hours trading.
Soren Launthof Hansen is a senior equity analyst at Denmark's A.L.
Sudbank and says Hims & Hers' decision will give Novo Nordisk and competitor Eli Lilly some breathing room as pricing pressure mounts across the obesity drug market.
I definitely think this is a tailwind for Nordisk and also Eli Lilly.
More than a million Americans are using compounding versions of a GLB1 product.
I think this will actually protect companies that do spend time and significant investments in new innovation.